BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mccolley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan MW. Risk factors for mortality before age 18 years in cystic fibrosis. Pediatr Pulmonol 2017;52:909-15. [DOI: 10.1002/ppul.23715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respir Med 2021:S2213-2600(21)00069-2. [PMID: 33965000 DOI: 10.1016/S2213-2600(21)00069-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cogen JD, Hall M, Loeffler DR, Gove N, Onchiri F, Sawicki GS, Fink AK. Linkage of the CF foundation patient registry with the pediatric health information system database. Pediatric Pulmonology 2019;54:721-8. [DOI: 10.1002/ppul.24272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
3 Jackson L, Waters V. Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros 2021;20:8-16. [PMID: 33172756 DOI: 10.1016/j.jcf.2020.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Mcgarry ME, Gibb ER, Oates GR, Schechter MS. Left Behind: The Potential Impact of CFTR Modulators on Racial and Ethnic Disparities in Cystic Fibrosis. Paediatric Respiratory Reviews 2021. [DOI: 10.1016/j.prrv.2021.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Schlüter DK, Griffiths R, Adam A, Akbari A, Heaven ML, Paranjothy S, Nybo Andersen AM, Carr SB, Pressler T, Diggle PJ, Taylor-Robinson D. Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales. Thorax 2019;74:447-54. [PMID: 30026297 DOI: 10.1136/thoraxjnl-2018-211706] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
6 Orenstein DM, Abood RN. Cost(s) of caring for patients with cystic fibrosis: . Current Opinion in Pediatrics 2018;30:393-8. [DOI: 10.1097/mop.0000000000000625] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Keogh RH, Seaman SR, Barrett JK, Taylor-Robinson D, Szczesniak R. Dynamic Prediction of Survival in Cystic Fibrosis: A Landmarking Analysis Using UK Patient Registry Data. Epidemiology 2019;30:29-37. [PMID: 30234550 DOI: 10.1097/EDE.0000000000000920] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 6.3] [Reference Citation Analysis]
8 Kapnadak SG, Dimango E, Hadjiliadis D, Hempstead SE, Tallarico E, Pilewski JM, Faro A, Albright J, Benden C, Blair S, Dellon EP, Gochenour D, Michelson P, Moshiree B, Neuringer I, Riedy C, Schindler T, Singer LG, Young D, Vignola L, Zukosky J, Simon RH. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. Journal of Cystic Fibrosis 2020;19:344-54. [DOI: 10.1016/j.jcf.2020.02.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
9 Zolin A, Bossi A, Cirilli N, Kashirskaya N, Padoan R. Cystic Fibrosis Mortality in Childhood. Data from European Cystic Fibrosis Society Patient Registry. Int J Environ Res Public Health 2018;15:E2020. [PMID: 30223583 DOI: 10.3390/ijerph15092020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
10 Dittrich AM. [Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts]. Internist (Berl) 2017;58:1133-41. [PMID: 28963697 DOI: 10.1007/s00108-017-0327-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Hudock KM, Clancy JP. An update on new and emerging therapies for cystic fibrosis. Expert Opin Emerg Drugs 2017;22:331-46. [PMID: 29264936 DOI: 10.1080/14728214.2017.1418324] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
12 Lam GY, Goodwin J, Wilcox PG, Quon BS. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res 2021;7:00475-2020. [PMID: 33532475 DOI: 10.1183/23120541.00475-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Le TN, Anabtawi A, Putman MS, Tangpricha V, Stalvey MS. Growth failure and treatment in cystic fibrosis. J Cyst Fibros 2019;18 Suppl 2:S82-7. [PMID: 31679733 DOI: 10.1016/j.jcf.2019.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
14 Collins R, Singh B, Payne DN, Bharat C, Noffsinger W, Dhaliwal SS, O'Dea C, Mulrennan S. Effect of transfer from a pediatric to adult cystic fibrosis center on clinical status and hospital attendance. Pediatr Pulmonol 2021;56:2029-35. [PMID: 33793092 DOI: 10.1002/ppul.25398] [Reference Citation Analysis]
15 Muilwijk D, Bierlaagh M, van Mourik P, Kraaijkamp J, van der Meer R, van den Bor R, Heijerman H, Eijkemans R, Beekman J, van der Ent K. Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators. J Pers Med 2021;11:1376. [PMID: 34945848 DOI: 10.3390/jpm11121376] [Reference Citation Analysis]
16 Dongarwar D, Garcia BY, Miller K, Salihu HM. Assessment of hospitalization rates, factors associated with hospitalization and in-patient mortality in pediatric patients with cystic fibrosis. J Natl Med Assoc 2021:S0027-9684(21)00190-5. [PMID: 34479733 DOI: 10.1016/j.jnma.2021.08.038] [Reference Citation Analysis]
17 Schechter MS, Schmidt HJ, Williams R, Norton R, Taylor D, Molzhon A. Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosis. Journal of Cystic Fibrosis 2018;17:769-78. [DOI: 10.1016/j.jcf.2018.06.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
18 McColley SA, Martiniano SL, Ren CL, Sontag MK, Rychlik K, Balmert L, Elbert A, Wu R, Farrell PM. Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening. J Cyst Fibros 2022:S1569-1993(22)00628-2. [PMID: 35871976 DOI: 10.1016/j.jcf.2022.07.010] [Reference Citation Analysis]
19 Singh SB, McLearn-Montz AJ, Milavetz F, Gates LK, Fox C, Murry LT, Sabus A, Porterfield HS, Fischer AJ. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor. Pediatr Pulmonol 2019;54:1200-8. [PMID: 31012285 DOI: 10.1002/ppul.24341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
20 Shakkottai A, O'Brien LM, Nasr SZ, Chervin RD. Sleep disturbances and their impact in pediatric cystic fibrosis. Sleep Med Rev 2018;42:100-10. [PMID: 30093360 DOI: 10.1016/j.smrv.2018.07.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
21 Zampoli M, Verstraete J, Frauendorf M, Kassanjee R, Workman L, Morrow BM, Zar HJ. Cystic fibrosis in South Africa: spectrum of disease and determinants of outcome. ERJ Open Res 2021;7:00856-2020. [PMID: 34350279 DOI: 10.1183/23120541.00856-2020] [Reference Citation Analysis]
22 Fink AK, Loeffler DR, Marshall BC, Goss CH, Morgan WJ. Data that empower: The success and promise of CF patient registries. Pediatr Pulmonol 2017;52:S44-51. [PMID: 28910520 DOI: 10.1002/ppul.23790] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
23 Talamo Guevara M, McColley SA. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Expert Opin Drug Saf 2017;16:1305-11. [PMID: 28846049 DOI: 10.1080/14740338.2017.1372419] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
24 Barbosa RRB, Liberato FMG, Freitas Coelho P, Vidal PDR, Carvalho RBCO, Donadio MVF. Sleep‐disordered breathing and markers of morbidity in children and adolescents with cystic fibrosis. Pediatr Pulmonol 2020;55:1974-83. [DOI: 10.1002/ppul.24780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 McColley SA. Predicting the course of nutrition and lung disease in infants and children with cystic fibrosis. J Cyst Fibros 2020;19:847-9. [PMID: 32674985 DOI: 10.1016/j.jcf.2020.07.006] [Reference Citation Analysis]
26 Dickinson KM, Psoter KJ, Riekert KA, Collaco JM. Association between insurance variability and early lung function in children with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)01290-X. [PMID: 34175244 DOI: 10.1016/j.jcf.2021.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
28 McDonald CM, Alvarez JA, Bailey J, Bowser EK, Farnham K, Mangus M, Padula L, Porco K, Rozga M. Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-Based Nutrition Practice Guideline. J Acad Nutr Diet 2021;121:1591-1636.e3. [PMID: 32565399 DOI: 10.1016/j.jand.2020.03.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Le TN, Schechter MS. Origins of growth deficiencies in cystic fibrosis. Thorax 2019;74:423-4. [DOI: 10.1136/thoraxjnl-2019-213076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Corbera-hincapie MA, Atteih SE, Stransky OM, Weiner DJ, Yann IM, Kazmerski TM. Experiences and Perspectives of Individuals with Cystic Fibrosis and Their Families Related to Food Insecurity. Nutrients 2022;14:2573. [DOI: 10.3390/nu14132573] [Reference Citation Analysis]
31 McGarry ME, Huang CY, Nielson DW, Ly NP. Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States. J Cyst Fibros 2021;20:424-31. [PMID: 33162303 DOI: 10.1016/j.jcf.2020.10.002] [Reference Citation Analysis]
32 Solomon M, Mallory GB. Lung transplant referrals for individuals with cystic fibrosis: A pediatric perspective on the cystic fibrosis foundation consensus guidelines. Pediatr Pulmonol 2021;56:465-71. [PMID: 33300243 DOI: 10.1002/ppul.25215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Thaker V, Carter B, Putman M. Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database Syst Rev 2021;8:CD008901. [PMID: 34424546 DOI: 10.1002/14651858.CD008901.pub5] [Reference Citation Analysis]
34 Ioannou P, Kouis P, Kakkoura MG, Kaliva M, Toliopoulou A, Andreou K, Behan L, Lucas JS, Papanikolaou V, Charalambous G, Middleton N, Yiallouros PK. Health related quality of life in adult primary Ciliary dyskinesia patients in Cyprus: development and validation of the Greek version of the QOL-PCD questionnaire. Health Qual Life Outcomes 2020;18:105. [PMID: 32321519 DOI: 10.1186/s12955-020-01360-w] [Reference Citation Analysis]
35 Williams WA 2nd, Jain M, Laguna TA, McColley SA. Preferences for disclosing adverse childhood experiences for children and adults with cystic fibrosis. Pediatr Pulmonol 2021;56:921-7. [PMID: 33369260 DOI: 10.1002/ppul.25243] [Reference Citation Analysis]
36 Savant AP, Mccolley SA. Cystic fibrosis year in review 2017. Pediatr Pulmonol 2018;53:1307-17. [DOI: 10.1002/ppul.24081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Konstan MW, Pasta DJ, VanDevanter DR, Wagener JS, Morgan WJ; Scientific Advisory Group and the Investigators and Coordinators of ESCF. Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. Pediatr Pulmonol 2021;56:823-36. [PMID: 33434406 DOI: 10.1002/ppul.25248] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Kapnadak SG, Ramos KJ, Dellon EP. Enhancing care for individuals with advanced cystic fibrosis lung disease. Pediatr Pulmonol 2021;56 Suppl 1:S69-78. [PMID: 32609949 DOI: 10.1002/ppul.24937] [Reference Citation Analysis]
39 Li SS, Hayes D, Tobias JD, Morgan WJ, Tumin D. Health insurance and use of recommended routine care in adults with cystic fibrosis. Clin Respir J 2018;12:1981-8. [DOI: 10.1111/crj.12767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
40 Rachel M, Topolewicz S, Śliwczyński A, Galiniak S. Managing Cystic Fibrosis in Polish Healthcare. Int J Environ Res Public Health 2020;17:E7630. [PMID: 33092012 DOI: 10.3390/ijerph17207630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Siuba M, Attaway A, Zein J, Wang X, Han X, Strausbaugh S, Jacono F, Dasenbrook EC. Mortality in Adults with Cystic Fibrosis Requiring Mechanical Ventilation. Cross-Sectional Analysis of Nationwide Events. Ann Am Thorac Soc 2019;16:1017-23. [PMID: 31026405 DOI: 10.1513/AnnalsATS.201804-268OC] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
42 Koutsokera A, Varughese RA, Sykes J, Orchanian-cheff A, Shah PS, Chaparro C, Tullis E, Singer LG, Stephenson AL. Pre-transplant factors associated with mortality after lung transplantation in cystic fibrosis: A systematic review and meta-analysis. Journal of Cystic Fibrosis 2019;18:407-15. [DOI: 10.1016/j.jcf.2018.10.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
43 Girón Moreno RM, García-Clemente M, Diab-Cáceres L, Martínez-Vergara A, Martínez-García MÁ, Gómez-Punter RM. Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics (Basel) 2021;10:486. [PMID: 33922413 DOI: 10.3390/antibiotics10050486] [Reference Citation Analysis]
44 Sankararaman S, Schindler T, Sferra TJ. Management of Exocrine Pancreatic Insufficiency in Children. Nutrition in Clinical Practice 2019;34:S27-42. [DOI: 10.1002/ncp.10388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Kouis P, Goutaki M, Halbeisen FS, Gioti I, Middleton N, Amirav I, Barbato A, Behan L, Boon M, Emiralioglu N, Haarman EG, Karadag B, Koerner-Rettberg C, Lazor R, Loebinger MR, Maitre B, Mazurek H, Morgan L, Nielsen KG, Omran H, Özçelik U, Price M, Pogorzelski A, Snijders D, Thouvenin G, Werner C, Zivkovic Z, Kuehni CE, Yiallouros PK; Israeli PCD Consortium., Italian PCD Consortium., Swiss PCD Group., French Reference Centre for Rare Lung Diseases., PCD Italian Consortium., French Reference Centre for Rare Lung Diseases. Prevalence and course of disease after lung resection in primary ciliary dyskinesia: a cohort & nested case-control study. Respir Res 2019;20:212. [PMID: 31533829 DOI: 10.1186/s12931-019-1183-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
46 Vandenbroucke NJ, Zampoli M, Morrow B. Lung function determinants and mortality of children and adolescents with cystic fibrosis in South Africa 2007‐2016. Pediatr Pulmonol 2020;55:1381-7. [DOI: 10.1002/ppul.24726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Shakkottai A, Nasr SZ, Hassan F, Irani S, O'Brien LM, Chervin RD. Sleep-disordered breathing in cystic fibrosis. Sleep Med 2020;74:57-65. [PMID: 32841845 DOI: 10.1016/j.sleep.2020.05.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Martiniano SL, Elbert AA, Farrell PM, Ren CL, Sontag MK, Wu R, McColley SA. Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study. Pediatr Pulmonol 2021;56:3758-67. [PMID: 34469079 DOI: 10.1002/ppul.25658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]